| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 11,144 | 25,201 | ||
| Marketable securities, short-term | 136,115 | 158,747 | ||
| Accounts receivable | 242 | 71 | ||
| Contract assets | 860 | 753 | ||
| Other receivables | 1,828 | 1,956 | ||
| Prepaid expenses and other current assets | 5,317 | 5,778 | ||
| Total current assets | 155,506 | 192,506 | ||
| Investments in equity securities | 143 | 132 | ||
| Marketable securities, long-term | 11,953 | 0 | ||
| Property and equipment, net | 7,598 | 8,179 | ||
| Operating lease, right of use assets | 16,004 | 16,461 | ||
| Other assets | 3,780 | 3,625 | ||
| Total assets | 194,984 | 220,903 | ||
| Accounts payable | 3,804 | 3,243 | ||
| Accrued expenses and other current liabilities | 19,350 | 20,528 | ||
| Operating lease liabilities, current | 2,687 | 2,287 | ||
| Deferred revenue (1,865 and 2,487 from related party as of september30, 2025, and december31, 2024, respectively) | 2,217 | 2,829 | ||
| Total current liabilities | 28,058 | 28,887 | ||
| Deferred revenue, net of current portion (0 and 1,243 from related party as of september30, 2025, and december31, 2024, respectively) | 1,756 | 1,772 | ||
| Mskcc success payments liability | 0 | 0 | ||
| Operating lease liabilities, non-current | 22,777 | 23,564 | ||
| Deferred tax liabilities | 548 | 548 | ||
| Total liabilities | 53,139 | 54,771 | ||
| Common stock, par value 0.0001 per share, 300,000,000 shares authorized as of september30, 2025, and december31, 2024 93,468,038 and 92,378,577 shares issued and outstanding as of september30, 2025, and december31, 2024, respectively | 9 | 9 | ||
| Additional paid-in-capital | 711,770 | 708,562 | ||
| Accumulated other comprehensive income | 93 | 40 | ||
| Accumulated deficit | -570,027 | -542,479 | ||
| Total stockholders equity | 141,845 | 166,132 | ||
| Total liabilities and stockholders equity | 194,984 | 220,903 | ||
Caribou Biosciences, Inc. (CRBU)
Caribou Biosciences, Inc. (CRBU)